Clinical Trial Update: Interleukin-2 Treatment for Wiskott-Aldrich Syndrome [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating interleukin-2 therapy for Wiskott-Aldrich syndrome and X-linked thrombocytopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wiskott-aldrich Syndrome
• X-linked Thrombocytopenia

Drugs mentioned

• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Soma Jyonouchi | Conditions: Wiskott-Aldrich Syndrome (WAS), X-linked Thrombocytopenia | Phase 1 | Status: COMPLETED